WO2021210868A1 - 신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도 - Google Patents
신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- WO2021210868A1 WO2021210868A1 PCT/KR2021/004592 KR2021004592W WO2021210868A1 WO 2021210868 A1 WO2021210868 A1 WO 2021210868A1 KR 2021004592 W KR2021004592 W KR 2021004592W WO 2021210868 A1 WO2021210868 A1 WO 2021210868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- bond
- dimeric
- dimeric peptide
- independently
- Prior art date
Links
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title abstract description 31
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title abstract description 31
- 210000004027 cell Anatomy 0.000 claims abstract description 97
- 238000001338 self-assembly Methods 0.000 claims abstract description 22
- 239000002105 nanoparticle Substances 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 197
- 239000000539 dimer Substances 0.000 claims description 59
- 235000001014 amino acid Nutrition 0.000 claims description 42
- 229940024606 amino acid Drugs 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 231100000135 cytotoxicity Toxicity 0.000 claims description 40
- 230000003013 cytotoxicity Effects 0.000 claims description 40
- 230000035699 permeability Effects 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 235000018417 cysteine Nutrition 0.000 claims description 20
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- -1 penicylamine (Pen) Chemical compound 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 7
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 7
- 229940055619 selenocysteine Drugs 0.000 claims description 7
- 235000016491 selenocysteine Nutrition 0.000 claims description 7
- ITYQPPZZOYSACT-UHFFFAOYSA-N 2-(2,2-dimethylpropylamino)acetic acid Chemical compound CC(C)(C)CNCC(O)=O ITYQPPZZOYSACT-UHFFFAOYSA-N 0.000 claims description 6
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 239000011149 active material Substances 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 101150055934 mgrA gene Proteins 0.000 claims description 6
- 101150002988 norR gene Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 claims description 5
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 229940088623 biologically active substance Drugs 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- IFPQOXNWLSRZKX-UHFFFAOYSA-N 2-amino-4-(diaminomethylideneamino)butanoic acid Chemical compound OC(=O)C(N)CCN=C(N)N IFPQOXNWLSRZKX-UHFFFAOYSA-N 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- AHLFJIALFLSDAQ-UHFFFAOYSA-N 2-(pentylazaniumyl)acetate Chemical compound CCCCCNCC(O)=O AHLFJIALFLSDAQ-UHFFFAOYSA-N 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 3
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- 101100447126 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) fprA gene Proteins 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000012650 click reaction Methods 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 101150029304 norV gene Proteins 0.000 claims description 3
- 239000000710 homodimer Substances 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 15
- 210000003527 eukaryotic cell Anatomy 0.000 abstract description 2
- 239000000178 monomer Substances 0.000 description 19
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 18
- 229960000485 methotrexate Drugs 0.000 description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102100041023 Coronin-2A Human genes 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 101000748858 Homo sapiens Coronin-2A Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical group C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 2
- 101710187795 60S ribosomal protein L15 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101150062794 FH10 gene Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005660 hydrophilic surface Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XIMIGUBYDJDCKI-UHFFFAOYSA-N diselenium Chemical compound [Se]=[Se] XIMIGUBYDJDCKI-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel alpha-helical bidirectional cell penetrating peptides and uses thereof.
- the cell-penetrating peptide of the present invention has the property of self-assembly of nanoparticles, and is permeated into cells at a nanomolar concentration in eukaryotic cells, and thus can be usefully used to deliver drugs, etc., which are difficult to penetrate into cells.
- CPP Cell Penetrating Peptides
- the modulator may be covalently linked to CPP or form a complex with a cell penetrating peptide.
- CPP alone, it is possible to deliver a modulator that was only capable of intracellular delivery at a high concentration at a low concentration.
- the present inventors confirmed the fact that, in a previous study, when a peptide containing a covalent linkage site at a specific amino acid position was prepared as a dimer and the alpha helix was maximized, cell permeability was remarkably improved and delivered into cells even at nanomolar concentration. Yes (WO 2015/057009).
- leucine is substituted with cysteine (LK-2) at the i and i+7 positions of the hydrophobic side of the double-sided alpha-helical peptide (LK-1) composed of Leu and Lys, two disulfide bonds are formed under cysteine oxidation conditions.
- LK-3 is a dimeric peptide (LK-3), and LK-3 has the characteristic of having cell permeability even at several nanomolar concentrations.
- LK-3 is a dimeric bundle peptide consisting of a total of 16 amino acids, which is not suitable for commercial use, such as a slow manufacturing process and unsatisfactory cytotoxicity.
- An object of the present invention is to provide a commercially available cell-penetrating peptide in consideration of cell-penetrating ability, simplification of the manufacturing process, material properties such as solubility in water of the dimeric peptide, and cytotoxicity.
- Another object of the present invention is to provide a platform technology capable of delivering a biologically active material, such as a therapeutic drug, into cells using the cell-penetrating peptide.
- the present invention provides a dimeric peptide comprising a peptide represented by the following formula (1) as a unit.
- X 1 , X 4 , X 5 and X 8 are each independently a hydrophobic amino acid
- X 3 , X 6 , X 7 and X 10 are each independently a hydrophilic amino acid
- X 2 and X 9 are each independently amino acids that form a bond so that each monomeric peptide is linked to each other at at least one position of X 2 and X 9 to form a dimeric peptide.
- the present invention also provides a pharmaceutical composition comprising the dimeric peptide and a biologically active substance.
- the alpha-helical double-sided peptide according to the present invention exhibits high cell permeability as a characteristic of self-assembly of nanoparticles. Accordingly, the peptides of the present invention can effectively deliver various biologically active substances into cells, and can also minimize cytotoxicity after cell permeation, and thus can be usefully used in the field of prevention or treatment of diseases.
- dimeric peptide of the present invention is economically useful because of its rapid formation rate from the monomer and is suitable for commercial use.
- Figure 2a shows the formation rate (measured by the concentration change of the monomer) of various dimeric cell-penetrating peptides.
- the monomer concentration (%) at 24 hours is low in the order of FK10, LK10, FR10, IR10, LR10, IK10, NpgR10, LH10, VK10, FH10, NpgK10 (however, FR10, IR10, LR10 is the lowest at 8 hours) After that, the graphs almost overlap).
- Figure 2b shows the schematic structure of a dimeric peptide with the characteristics of nanoparticle self-assembly.
- Figure 3 shows a schematic of the modification of the monomer spacing in the dimer: a) 16-mer (LK-3) dimer; b) 10-mer dimers.
- Figure 6a shows the correlation between the cell permeability and cytotoxicity of the dimeric peptide of the present invention.
- Figure 6b shows the tendency of nanoparticle self-assembly of the dimeric peptide of the present invention as a state change of the retention time for each temperature using reverse phase chromatography ( ⁇ Rt values at the highest temperature (Temp) in each graph are AcLR10 mono, diFR10 , diLR10, LK03, helix A, diLK10 (nearly overlapping with helix A), diNpgR10, and diNpgK10 in that order.
- ⁇ Rt values at the highest temperature (Temp) in each graph are AcLR10 mono, diFR10 , diLR10, LK03, helix A, diLK10 (nearly overlapping with helix A), diNpgR10, and diNpgK10 in that order.
- Figure 6c shows the correlation between the propensity for self-assembly of nanoparticles of the dimeric peptide of the present invention and cytotoxicity.
- FIG. 9 shows intracellular delivery of an antibody using a cell-penetrating peptide conjugated with streptavidin and biotin.
- the present invention provides a dimeric cell-penetrating peptide comprising a 10-mer peptide consisting of a total of 10 amino acids as a unit.
- the 10-mer monomeric peptide may include a hydrophobic amino acid and a hydrophilic amino acid in an appropriate ratio, such as 1:1, more specifically, 4 each, and each monomer is linked to each other via a bond at one or two positions to form a dimer. peptides can be formed.
- the present inventors tried to provide an optimal cell penetrating peptide in consideration of the dimer formation rate, cell permeability and cytotoxicity, and the correlation between the characteristics of self-assembly of nanoparticles and cell permeability. Specifically, it was confirmed that the monomeric peptide consisting of 10 amino acids was the most optimal in terms of the dimer formation rate, and it was found that when it was made into a dimer bundle, it had the optimal cell permeability. In particular, the dimeric peptide composed of 10 amino acids has excellent cell permeability at a nanomolar level, and has low cytotoxicity compared to the conventionally known 16 amino acid dimeric peptide, making it suitable for use in vivo. In addition, since the 10-mer short cell-penetrating peptide penetrates more rapidly into the cell compared to the existing 16-mer peptide, there is an advantage in that the modulator can be rapidly delivered into the cell.
- the present invention provides a dimeric peptide comprising a peptide represented by the following formula (1) as a unit.
- X 1 , X 4 , X 5 and X 8 are each independently a hydrophobic amino acid
- X 3 , X 6 , X 7 and X 10 are each independently a hydrophilic amino acid
- X 2 and X 9 are each independently amino acids that form a bond so that each monomeric peptide is linked to each other at at least one position of X 2 and X 9 to form a dimeric peptide,
- X 1 is N-terminal and X 10 is C-terminal.
- the dimeric peptide may be an alpha-helical double-sided peptide in the form of a homodimer or a heterodimer.
- a fluorescent substance, biotin, or lipid when additionally linked, it may be used in the form of a heterodimer.
- peptide is an amino acid polymer, and may include not only natural amino acids but also non-natural amino acids as constituents.
- the type of amino acid constituting the peptide is not limited as long as it is capable of maintaining an alpha helical structure while exhibiting both sides, and a hydrophobic amino acid or a hydrophilic amino acid known to those skilled in the art may be appropriately selected and used.
- the present inventors have revealed through a previous study that the peptide with increased alpha helix increased the intracellular permeability and that the alpha helix was removed from the cell, thereby reducing the toxicity of the peptide (WO 2015/057009).
- the hydrophobic amino acid is leucine (L), isoleucine (I), phenylalanine (F), valine (V), norvaline (norV), tryptophan (W), pentylglycine (pg), neopentylglycine (Npg), and cyclohexylalanine (Cha) may be selected from the group consisting of.
- X 1 , X 4 , X 5 and X 8 are each independently leucine (L), isoleucine (I), phenylalanine (F), valine (V), norvaline (norV), tryptophan (W), It may be a hydrophobic amino acid selected from the group consisting of pentylglycine (pg), neopentylglycine (Npg), and cyclohexylalanine (Cha).
- the hydrophilic amino acid is lysine (K), arginine (R), homoarginine (hR), norarginine (norR), histidine (H), ornithine (O), diaminobutanoic acid (Dab), and diaminopropanoic acid (Dap) may be selected from the group consisting of.
- X 3 , X 6 , X 7 and X 10 are each independently lysine (K), arginine (R), homoarginine (hR), noarginine (norR), histidine (H), ornithine It may be a hydrophilic amino acid selected from the group consisting of (O), diaminobutanoic acid (Dab), and diaminopropanoic acid (Dap).
- the dimeric peptide of the present invention is one in which monomeric peptides are formed by bonding to each other.
- the bonding position may be any one or both positions of X 2 and X 9 .
- each of X 2 and X 9 may be independently selected from any amino acid that forms a bond such that each monomeric peptide is linked to each other at at least one position of X 2 and X 9 to form a dimeric peptide, e.g.
- X 2 and X 9 are each independently an amino acid selected from the group consisting of cysteine (C), homocysteine (Hcy), penicylamine (Pen), selenocysteine (Sec, U) and leucine (L), , provided that X 2 and X 9 may not be leucine (L) at the same time.
- the bond formed between the monomeric peptides may include any type of bond linking the peptides to exhibit the desired properties according to the present invention, and may include, for example, a covalent bond.
- the covalent bond is not particularly limited as long as it is a type of covalent bond capable of improving alpha helix without inhibiting the function of the peptide, but for example, a disulfide bond between cysteines, a diselenide bond, an ester bond, a maleic bond It may be at least one bond selected from the group consisting of a mid bond, a thioester bond, a thioether bond, and a bond by a click reaction.
- the covalent bond is a disulfide bond between cysteine (C), homocysteine (Hcy) or penicylamine (Pen), a diselenide bond between selenocysteine (See, U), an ester bond, and participates in a reaction. If it contains a maleimide bond, a thioester bond, a thioether bond using a thiol functional group that can It may be at least one selected from the group consisting of.
- disulfide bond When a disulfide bond (disulfide bond) is formed between two monomers of a dimeric peptide, when cysteine (C) is used in the monomer, four atoms (CSSC) exist between the two monomeric peptide backbones.
- CSSC cysteine
- Hcy homocysteine
- the distance between the two monomeric peptide backbones can be adjusted to 5 bonding distances (CCSSC or CSSCC) or 6 bonding distances (CCSSCC).
- a dimer in which one cysteine and one homocysteine are oxidatively linked may be used.
- cysteine diselenide, cysteine, or penicylamine may be hybridized or an ester disulfide bond may be formed.
- each monomeric peptide maintains the N-to-C-terminal direction and is linked in a parallel direction, or one of the two peptides is N-terminal to C-terminal, and the other is C-to-N-terminal. , that is, may be connected in an anti-parallel direction. In one embodiment, each monomeric peptide is linked in an antiparallel direction to each other.
- the dimeric peptide may be lipidated at the N-terminus with a fatty acid.
- the dimeric peptide may have a C 6 to C 16 fatty acid bonded thereto at the position of X 1 . It is possible to further improve cell permeability through such fatty acid binding.
- the present invention provides a dimeric peptide comprising a peptide represented by the following formula (1) as a unit.
- X 1 , X 4 , X 5 , or X 8 are each independently leucine (L), isoleucine (I), phenylalanine (F), valine (V), neopentylglycine (Npg), or cyclohexylalanine (Cha) )ego,
- X 3 , X 6 , X 7 and X 10 are each independently lysine (K), arginine (R), homoarginine (hR), norarginine (norR), histidine (H), ornithine (O) , diaminobutanoic acid (Dab), or diaminopropanoic acid (Dap),
- X 2 and X 9 are each independently cysteine (C), homocysteine (Hcy), penicylamine (Pen), selenocysteine (Sec, U) or leucine (L), provided that X 2 and X 9 are simultaneously leucine (L) is not.
- X 1 , X 4 , X 5 , or X 8 may each independently be phenylalanine (F), isoleucine (I), leucine (I) or neopentylglycine (Npg).
- X 3 , X 6 , X 7 and X 10 may each independently be arginine (R) or lysine (K).
- X 1 , X 4 , X 5 , or X 8 is each independently leucine (L), cyclohexylalanine (Cha), or phenylalanine (F), and X 2 and X 9 is cysteine (C), and X 3 , X 6 , X 7 and X 10 are all arginine (R), and may be excluded from the scope of the present invention.
- X 2 and X 9 in Formula 1 are cysteine (C)
- X 3 , X 6 , X 7 and X 10 are all arginine (R)
- X 1 , X 4 , X 5 , or X 8 are each independently not leucine (L), cyclohexylalanine (Cha), or phenylalanine (F).
- the present invention also provides the monomeric peptide itself as mentioned above.
- the monomeric peptide of the present invention is represented by the following formula (1).
- X 1 to X 10 are as defined above.
- the monomeric peptide of the present invention is a peptide represented by Formula 1 or a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 8 to 46.
- the term “monomeric peptide” refers to a peptide that is the basis for preparing a dimeric peptide, and may be used interchangeably with “monomeric peptide”.
- the dimeric peptide of the present invention may include a monomeric peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 8 to 26.
- the dimeric peptide of the present invention may include a monomeric peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 8 to 26.
- the dimeric peptide of the present invention may include a monomeric peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 8 to 26.
- the monomeric peptide consists of 10 amino acids, and is linked to each other through a covalent bond as described above at one or more positions of X 2 and/or X 9 to form a dimeric peptide.
- dimeric peptide according to the present invention it is possible to secure cell permeability even at a low concentration in the range of nanomolar concentration.
- a concentration of at least micromolar is required to deliver biologically active substances into cells. It was confirmed that it can be usefully used to effectively deliver an active substance.
- a desired effect can be exhibited even when the biologically active material is also used at a very low concentration compared to the prior art.
- a low concentration of a cell penetrating peptide and a low concentration of a biologically active substance may be sufficient conditions to minimize cytotoxicity.
- cell-penetrating peptides are the most important points to be considered when using cell-penetrating peptides. Since cell-penetrating peptides themselves have cell-penetrating ability, they can cause toxicity when they enter cells. That is, cell permeability and toxicity may be related to each other. Therefore, it is important to develop a peptide that has high cell permeability and can also minimize its toxicity. In the case of the dimeric peptide according to the present invention, it shows cell permeability even in a few nanomoles to several hundred nanomoles, and the ratio of cell permeability to cytotoxicity is 1/10 or less. If the physiologically active substance is delivered into the cell at a low concentration, the cytotoxicity caused by the cell-penetrating peptide can be minimized.
- the covalent bond between the dimers is broken to form a monomeric peptide. If the covalent bond is maintained in the cell and exists in the form of a dimeric peptide, since the dimeric peptide generally has excellent binding ability to DNA or RNA, cytotoxicity may occur.
- the peptide unit in which the covalent bond in the cytoplasm is broken can be easily hydrolyzed by many proteolytic enzymes in the cell because the alpha helix is also rapidly reduced and the chemical stability is very low.
- the cell-permeable dimeric peptide according to the present invention not only exhibits excellent cell delivery ability, but also can achieve the desired effect even using a low concentration of biologically active substances, and can also minimize cytotoxicity by decomposition in cells.
- the ratio of cell permeability to cytotoxicity (IC 50 -1 ) at 62.5 nM of the dimeric peptide of the present invention is higher than that of a conventionally known peptide (eg, a dimer of LK-3), for example For example, it may be 130,000 or more.
- the ratio of the properties of nanoparticle self-assembly ( ⁇ Rt) to the cytotoxicity (IC 50 ⁇ 1 ) at 62.5 nM of the dimeric peptide of the present invention is a previously known peptide (eg, LK-3 of dimers), and may be, for example, 8 or more.
- the present invention provides a platform technology capable of delivering a biologically active material, such as a therapeutic drug, into a cell using the cell penetrating peptide.
- the dimeric peptide according to the present invention exhibits cell penetrating ability, it is possible to effectively use biologically active substances that have not been able to exhibit effective therapeutic efficacy, etc. because it is difficult to transfer into cells in the prior art.
- the present invention provides a pharmaceutical composition comprising the dimeric peptide and a biologically active substance.
- the biologically active material is a kind of cargo, and may be a material that binds to a cell membrane permeation domain and is delivered into a cell, thereby regulating a biological activity or function that regulates all physiological phenomena in a living body, for example, DNA, RNA, siRNA , an aptamer, a protein, an antibody, a small molecule compound, or a cytotoxic compound, but is not limited thereto.
- a substance or other carrier modulating biological activity or function may be additionally bound to the dimeric peptide according to the present invention, and in this case, the dimeric peptide and a substance or other carrier modulating biological activity or function may form a complex structure.
- the substance or carrier may be linked through, for example, a non-covalent bond or a covalent bond with the peptide of the present invention.
- the non-covalent bond may be, for example, at least one selected from the group consisting of a hydrogen bond, an electrostatic interaction, a hydrophobic interaction, a van der Waals interaction, a pi-pi interaction, and a cation-pi interaction.
- the covalent bond may be a degradable or non-degradable bond
- the degradable bond may be a disulfide bond, an acid-degradable bond, an ester bond, an anhydride bond, a biodegradable bond, or an enzymatically degradable bond
- the non-cleavable bond is an amide bond Or it may be a phosphate bond, but is not limited thereto.
- the cytotoxic compound may be linked by forming a non-covalent bond such as an electrostatic bond or a host-guest bond with the dimeric peptide, for example, Doxorubicin, Methotrexate, Paclitaxel, Cisplatin, Bleomycin, Taxol, Berberine or urcumin, but may be, However, the present invention is not limited thereto.
- a protein or antibody any type of drug that specifically binds to a specific target in a cell may be included, and may be introduced into the peptide in the form of being fused to the N-terminus or C-terminus.
- MTX methotrexate
- a dimeric peptide in drug-resistant cancer cells such as MCF7 or MDA-MB-231
- hydrophobic, physiologically active small molecules taxol, berberine, curcumin, etc.
- MTX methotrexate
- the drug efficacy of MTX was increased 20-fold or more in MTX-resistant MDA-MB-231 cells.
- cell penetrating peptides that act at concentrations as low as 40 times may also be provided.
- antibodies and proteins and protein drugs that are part of the antibody can be delivered into cells by linking them to the dimeric peptide, and oligonucleotide drugs (siRNA, asDNA, DNA, aptamer) can be linked to the dimeric peptide for intracellular delivery.
- oligonucleotide drugs siRNA, asDNA, DNA, aptamer
- the cell penetrating peptide may be bound to a biologically active material (eg, an antibody) through a non-covalent bond such as biotin-streptavidin, and delivered into the cell.
- composition according to the present invention may be prepared by further including one or more pharmaceutically acceptable carriers.
- a pharmaceutically acceptable carrier must be compatible with the active ingredient of the present invention, and contains saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or two or more of these components. They can be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats can be added as needed.
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, and the like.
- the formulation in a lyophilized form.
- a method commonly known in the art to which the present invention pertains may be used, and a stabilizer for freeze-drying may be added.
- it can be preferably formulated according to each disease or component by an appropriate method in the art.
- Each of the monomeric peptides in Table 1 was prepared and dimers were made by oxidation conditions in air.
- a monomeric peptide was synthesized using a solid-phase peptide synthesis method. Specifically, it was synthesized using a standard fluorenylmethyloxy carbonyl (Fmoc) solid-phase peptide in a peptide microwave synthesizer (CEM).
- Fmoc fluorenylmethyloxy carbonyl
- CEM peptide microwave synthesizer
- Link amide MBHA resin (0.59 mmole/g loading, 50 mg, 29.5 ⁇ mol) was used in Discover SPS. The resin was deprotected with 20% piperidine in DMF. Coupling reactions were performed using amino acids of each sequence, PyBOP and N-diisopropylethylamine (DIPEA).
- Fluorescence labeling was performed by reacting 5-TAMRA at the N-terminus of the synthesized peptide in the presence of HOBt, HCTU, and DIPEA.
- the synthesized peptides were separated from the resin using a cleavage cocktail for 2 h at room temperature (using 940 ⁇ L of Trifluoroacetic Acid, 25 ⁇ L of 1,2-ethaneedithiol, 25 ⁇ L of water and 10 ⁇ L of Triisopropylsilane).
- a dimer was prepared by oxidizing the prepared unit under oxidation conditions in air ( air oxidation on 0.1M NH 4 HCO 3 aqueous solution).
- the dimer was produced the fastest from the monomeric peptide (LK10) consisting of 10 amino acids, and more than 90% of the reaction was completed within 8 hours, and the reaction was almost 100% completed within 24 hours.
- LK10 monomeric peptide
- LK18 monomeric peptide
- 14 units the reaction proceeded relatively quickly, but it was slower than LK10, and in the case of 8 units (LK8) having a shorter length, it was observed that the reaction proceeded more slowly than LK10.
- LK12 12 amino acid unit
- the reaction rate was the fastest, but crystals were formed rapidly, and it was observed that the units produced various types of oligopeptides (trimers, tetramers, etc.) rather than forming dimers.
- LK10 the dimer production rate was faster even compared to the conventionally known 16-unit peptide (LK-2).
- Each of the monomeric peptides in Table 2 was prepared in the same manner as in Example 1, and dimers were formed by oxidation conditions.
- the dimer formation rate of the monomeric peptides of SEQ ID NOs: 8 to 17 was measured and compared with LK10, and the results are shown in FIG. 2A.
- the dimer was rapidly formed from the 10-mer unit, and in particular, FK10, LK10, FR10, IR10, LR10, and IK10 had a fast dimer formation rate almost similar to LK10, and the reaction was almost 100% complete within 24 hours, and NpgR10 was also In particular, it exhibited a high speed (Fig. 2a).
- the peptide of the present invention is an alpha-helical double-sided peptide in which the hydrophilic residue region and the hydrophobic residue region of the peptide are distinguished when forming an alpha helical form.
- the amino acid sequence of the unit was partially changed to reduce the double-sidedness, and it was confirmed whether a dimer of the unit was formed.
- RL10 (Ac-RCLRRLLRCL-NH 2 ) was prepared, and the dimer-forming ability was similarly confirmed.
- RL10 a part of kink was formed like LR10 8,10exch under oxidizing conditions, and an insoluble white precipitate was also formed at the same time.
- Peptides of Table 2 were prepared according to the same method as in Example 1.
- the process of adjusting the spacing between units is schematically shown in FIG. 3 .
- the distance between the monomeric peptides was divided into 4 atoms (CSSC; only Cys is used), 5 atoms (CCSSC or CSSCC), or 6 atoms (CCSSCC).
- one unit was prepared in the form of 5-TAMRA fluorescence attached to the N-terminus instead of Acetyl.
- Acetyl unit and 5-TAMRA fluorescent unit were mixed in a molar ratio of 1:1, and the dimer was formed in the form of a dimer under oxidation conditions in air to make a dimer labeled with only one fluorescence per dimer molecule, and then cell permeability was checked.
- the fluorescence-labeled peptide was treated with HeLa cells (5 x 10 4 cells/well), which are human-derived cells, and the ratio of the number of cells displaying fluorescence to the total number of cells was obtained through flow cytometry.
- the dimeric peptide according to the present invention exhibited excellent cell permeability at a level of several tens of nanomolar (FIG. 4a).
- 4B to 4D show the results of relatively comparing the fluorescence intensity of each dimer by treating the cells with the same concentration (62.5 nM) to measure the fluorescence intensity of the cells by flow cytometry.
- Cytotoxicity in HeLa cells was confirmed by the WST-1 assay method by treatment in 96 wells (1 x 10 4 cells/well) for 24 hours.
- HeLa cells were cultured in DMEM at 37 °C and 5% CO 2 conditions. After culturing each cell in a cell culture plate, the cells were removed with Trypsin, and 1x10 4 cells were seeded per well in a 96 well plate. After 24 hours, the peptide was added to the media and incubated for 24 hours at 37 °C, 5% CO 2 condition. 10 uL of WST-1 reagent was added per well and reacted for 30 minutes at 37 °C and 5% CO 2 conditions, and then UV absorbance was measured at 450/700 nm with a 96-well plate reader.
- Cytotoxicity was confirmed according to the interval of the dimer, and the cytotoxicity was low in the case of 5 atoms (CCSSC) in length (FIG. 5b).
- the diNpgK10, diLR10, diFR10, diIR10, and diNpgR10 dimeric peptides of the present invention had lower toxicity compared to cell permeability. That is, the ratio of cell permeability to cytotoxicity (IC 50 -1 ) to LK-3 (ie, cell permeability / cytotoxicity IC 50 -1 ) was about 130,000, and all of the dimeric peptides of the present invention were more than this. A high value was shown. This indicates that the dimeric peptide of the present invention has an appropriate balance between cell penetrating ability and cytotoxicity, and thus is suitable for use as a cell penetrating peptide compared to conventional LK-3.
- the tendency of self-assembly for each dimeric peptide was correlated with cytotoxicity.
- the dimeric peptides diFR10, di-LR10, diLK10, diNpgR10, and diNpgK10 of the present invention showed less cytotoxicity compared to the self-assembly tendency.
- the ratio of the nanoparticle self-assembly properties to the cytotoxicity (IC 50 ⁇ 1 ) for LK-3 was about 8, and all of the dimeric peptides of the present invention showed higher values than this.
- the cell permeability of the air oxidized dimer was similar to that of the antiparallel dimer and showed a completely different trend from that of the parallel dimer.
- a peptide in which methotrexate (MTX) is bound to the N-terminus of one unit of the dimer was synthesized according to a known method (Kim et al. Biomacromolecules 2016).
- Table 6 shows the IC50 values of MTX in three cell lines, and high IC50 values were shown in MDA-MB-231 cells, suggesting that MTX has resistance in these cells.
- MDA-MB-231 cells exhibiting resistance to MTX was confirmed by the WST-1 assay method described in Example 5.
- MDA-MB-231 cells were applied to a 96-well plate at a density of 2.5 x 10 3 cells/well and treated with MTX-bound peptide for 48 hours from the next day. The results are shown in Table 7.
- the IC 50 of the MTX-binding peptide was at the level of several tens of nanomolar. Considering that the IC 50 of the peptide itself is at the level of several micromolar, it was confirmed that the peptide according to the present invention can efficiently deliver MTX into cells with low toxicity at the nanomolar level.
- the hydrophobic drug cyclosporine (CsA) and the peptide were mixed and incubated at room temperature for 20 minutes to form a complex with the hydrophobic drug, and then treated in Jurkat cells (1.0 x 10 4 cells/well) for 4.5 hours.
- the amount of extracellularly secreted IL-2 was measured by the ELISA method to determine whether the anti-inflammatory effect of CsA was enhanced by the cell penetrating peptide diLR10 due to the relative decrease in IL-2 through the IC50 value.
- Intracellular delivery by non-covalent bonding with CsA was confirmed using CsA with fluorescence for peptides with various compositions of lysine and arginine. As a result, as shown in FIG. 8 , it was confirmed that diLR10 R3K had the best ability to deliver CsA into cells.
- AF488-bound BCl 2 antibody was delivered in the same way after biotin binding using EZ-LinkTM Sulfo-NHS-LC-LC-Biotin, and mitochondria were labeled using mitotracker red.
- mitotracker red As a result, green fluorescence by AF488 It was seen that there were many parts present at the same position as the red fluorescence by this mitotracker (results not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
SEQ ID NOs. | 단위체 (이합체) | 단위체 아미노산 서열 |
1 | LK-2 (LK-3) | Ac-LKKLCKLLKKLCKLAG-NH2 |
2 | LK8 (diLK8) | Ac-CKLLKKLC-NH2 |
3 | LK10 (diLK10) | Ac-LCKLLKKLCK-NH2 |
4 | LK12 (diLK12) | Ac-KLCKLLKKLCKL-NH2 |
5 | LK14 (diLK14) | Ac-KKLCKLLKKLCKLL-NH2 |
6 | LK16 (diLK16) | Ac-LKKLCKLLKKLCKLLK-NH2 |
7 | LK18 (diLK18) | Ac-LLKKLCKLLKKLCKLLKK-NH2 |
SEQ ID NOs. | 단위체 (이합체) | 단위체 아미노산 서열 |
8 | FK10 (diFK10) | Ac-FCKFFKKFCK-NH2 |
9 | FR10 (diFR10) | Ac-FCRFFRRFCR-NH2 |
10 | IR10 (diIR10) | Ac-ICRIIRRICR-NH2 |
11 | LR10 (diLR10) | Ac-LCRLLRRLCR-NH2 |
12 | IK10 (diIK10) | Ac-ICKIIKKICK-NH2 |
13 | L*R10 (di L*R10) | Ac-L*CRL*L*RRL*CR-NH2 (L* = Npg) |
14 | LH10 (diLH10) | Ac-LCHLLHHLCH-NH2 |
15 | VK10 (diVK10) | Ac-VCKVVKKVCK-NH2 |
16 | FH10 (diFH10) | Ac-FCHFFHHFCH-NH2 |
17 | L*K10 (di L*K10) | Ac-L*CKL*L*KKL*CK-NH2 (L* = Npg) |
18 | VH10 (diVH10) | Ac-VCHVVHHVCH-NH2 |
19 | L*H10 (di L*H10) | Ac-L*CHL*L*HHL*CH-NH2 (L* = Npg) |
20 | VR10 (diVR10) | Ac-VCRVVRRVCR-NH2 |
21 | IH10 (diIH10) | Ac-ICHIIHHICH-NH2 |
22 | L'K10 (diL'K10) | Ac-L'CKL'L'KKL'CK-NH2 (L' = Cha) |
23 | LR10C2L (diLR10C2L) | Ac-LLRLLRRLCR-NH2 |
24 | LR10C9L (diLR10C9L) | Ac-LCRLLRRLLR-NH2 |
25 | LO10 (diLO10) | Ac-LCOLLOOLCO-NH2 (O = Orn) |
26 | LK'10 (diLK'10) | Ac-LCK'LLK'K'LCK'-NH2 (K' = Dab) |
27 | LK''10 (diLK''10) | Ac-LCK''LLK''K''LCK''-NH2 (K'' = Dap) |
28 | LhR10 (diLhR10) | Ac-LChRLLhRhRLChR-NH2 |
29 | LR*10 (diLR*10) | Ac-LCR*LLR*R*LCR*-NH2 (R* = norR) |
30 | LR10R3K (diLR10R3K) | Ac-LCKLLRRLCR-NH2 |
31 | LR10R6K (diLR10R6K) | Ac-LCRLLKRLCR-NH2 |
32 | LR10R7K (diLR10R7K) | Ac-LCRLLRKLCR-NH2 |
33 | LR10R10K (diLR10R10K) | Ac-LCRLLRRLCK-NH2 |
34 | LR10R7,10K (diLR10R7,10K) | Ac-LCRLLRKLCK-NH2 |
35 | LR10R6,10K (diLR10R6,10K) | Ac-LCRLLKRLCK-NH2 |
36 | LR10R6,7K (diLR10R6,7K) | Ac-LCRLLKKLCR-NH2 |
37 | LR10R3,10K (diLR10R3,10K) | Ac-LCKLLRRLCK-NH2 |
38 | LR10R3,7K (diLR10R3,7K) | Ac-LCKLLRKLCR-NH2 |
39 | LR10R3,6K (diLR10R3,6K) | Ac-LCKLLKRLCR-NH2 |
LK-3 | diLK10 | diIK10 | diFK10 | diL*K10 | diLR10 | diIR10 | diFR10 | diL*R10 | |
IC50
(μM) |
4.44 | 12.4 | 11.4 | 9.36 | 10.3 | 18.9 | 14.4 | 18.2 | 13.8 |
ratio | 1.00 | 2.79 | 2.57 | 2.11 | 2.32 | 4.26 | 3.24 | 4.10 | 3.11 |
Cell line | NIH-3T3 | HeLa | MDA-MB-231 |
IC50 of MTX (μM) | 0.037 | ~0.031 | 0.97 |
IC50 (μM) | MTX | diLK10 | diLR10 | diNpgK10 | diNpgR10 |
IC50 of MTX conjugated peptide |
0.972 | 0.0459 | 0.0401 | 0.0246 | 0.0316 |
IC50 | - | ~13.7 | ~8.92 | ~5.84 | 11.2 |
CsA only | Complex w/ diLR10 | |
IC50 (nM) | 14 | 11 |
Claims (20)
- 하기 화학식 1로 표시되는 펩타이드를 단위체로 포함하는 이합체 펩타이드.<화학식 1>X1X2X3X4X5X6X7X8X9X10X1, X4, X5 및 X8은 각각 독립적으로 소수성 아미노산이고,X3, X6, X7 및 X10은 각각 독립적으로 친수성 아미노산이고,X2 및 X9는 각각 독립적으로 각 단위체 펩타이드가 X2 및 X9 중 적어도 하나의 위치에서 서로 연결되어 이합체 펩타이드를 형성할 수 있도록 결합을 형성하는 아미노산이고,X1은 N-말단이고 X10은 C-말단이다.
- 제1항에 있어서, X1, X4, X5 및 X8은 각각 독립적으로 루신(L), 이소루신(I), 페닐알라닌(F), 발린(V), 노르발린(norV), 트립토판(W), 펜틸글리신(pg), 네오펜틸글리신(Npg), 및 사이클로헥실알라닌(Cha)으로 이루어지는 군으로부터 선택되는 소수성 아미노산인, 이합체 펩타이드.
- 제1항에 있어서, X3, X6, X7 및 X10은 각각 독립적으로 라이신(K), 알지닌(R), 호모알지닌(hR), 노르알지닌(norR), 히스티딘(H), 오르니틴(O), 디아미노부탄산(Dab), 및 디아미노프로판산(Dap)으로 이루어지는 군으로부터 선택되는 친수성 아미노산인, 이합체 펩타이드.
- 제1항에 있어서, X2 및 X9는 각각 독립적으로 시스테인(C), 호모시스테인(Hcy), 페니실아민(Pen), 셀레노시스테인(Sec, U), 및 루신(L)으로 이루어지는 군으로부터 선택되는 아미노산이며, 단 X2 및 X9가 동시에 루신(L)은 아닌 것인, 이합체 펩타이드.
- 제1항에 있어서, X2 및 X9 중 적어도 하나의 위치에서 각 단위체 펩타이드 사이에 형성되는 결합은 공유결합인 것인, 이합체 펩타이드.
- 제5항에 있어서, 상기 공유결합은 이황화 결합, 디셀레나이드 결합, 에스테르 결합, 말레이미드 결합, 티오에스테르 결합, 티오에테르 결합 및 클릭 반응(click reaction)에 의한 결합으로 이루어지는 군으로부터 선택되는 하나 이상인 것인, 이합체 펩타이드.
- 제5항에 있어서, 상기 공유결합은 시스테인(C), 호모시스테인(Hcy) 또는 페니실아민(Pen) 사이의 이황화 결합, 셀레노시스테인(See, U) 사이의 디셀레나이드 결합, 에스테르 결합, 반응에 참여할 수 있는 티올 기능기를 이용한 말레이미드 결합, 티오에스테르 결합, 티오에테르 결합, 및 클릭 반응을 유발할 수 있는 삼중결합이나 아지드 그룹을 가지는 비천연 아미노산을 포함하는 경우 클릭 반응(click reaction)에 의한 결합으로 이루어지는 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 이합체 펩타이드.
- 제1항에 있어서, X1의 위치에서 C6 내지 C12 지방산이 결합되어 있는 것인, 이합체 펩타이드.
- 제1항에 있어서,X1, X4, X5, 또는 X8은 각각 독립적으로 루신(L), 이소루신(I), 페닐알라닌(F), 발린(V), 네오펜틸글리신(Npg), 또는 사이클로헥실알라닌(Cha)이고,X3, X6, X7 및 X10은 각각 독립적으로 라이신(K), 알지닌(R), 호모알지닌(hR), 노르알지닌(norR), 히스티딘(H), 오르니틴(O), 디아미노부탄산(Dab), 또는 디아미노프로판산(Dap)이고,X2 및 X9는 각각 독립적으로 시스테인(C), 호모시스테인(Hcy), 페니실아민(Pen), 셀레노시스테인(Sec, U), 또는 루신(L)이며, 단 X2 및 X9가 동시에 루신(L)은 아닌 것인,이합체 펩타이드.
- 제1항에 있어서, 동종 이합체(homodimer) 또는 이종 이합체(heterodimer) 형태의 알파나선형 양면성 펩타이드인, 이합체 펩타이드.
- 제1항에 있어서, 각 단위체 펩타이드는 서로 역평행(anti-parallel) 방향으로 연결된 것인, 이합체 펩타이드.
- 제1항에 있어서, 단위체에서는 세포 투과 능력이 미미하나, 이합체로 결합하였을 때 나노파티클 자가조립의 특징을 가지며, 나노몰 농도에서 세포 투과 능력을 나타내는, 이합체 펩타이드.
- 제1항에 있어서, 상기 이합체 펩타이드의 62.5 nM에서의 세포 독성(IC50 -1)에 대한 세포 투과능의 비율이 130,000 이상인 것인, 이합체 펩타이드.
- 제1항에 있어서, 상기 이합체 펩타이드의 62.5 nM에서의 세포 독성(IC50 -1)에 대한 나노파티클 자가조립의 특성(ΔΔRt)의 비율이 8 이상인, 이합체 펩타이드.
- 제1항에 있어서, 상기 화학식 1로 표시되는 펩타이드는 서열번호 3 및 8 내지 46으로 이루어지는 군으로부터 선택된 아미노산 서열을 포함하는 것인, 이합체 펩타이드.
- 하기 화학식 1로 표시되는 펩타이드.<화학식 1>X1X2X3X4X5X6X7X8X9X10X1 내지 X10은 각각 독립적으로 제1항 또는 제9항에 정의된 바와 같다.
- 제1항 내지 제15항 중 어느 한 항에 따른 이합체 펩타이드 및 생물학적 활성물질을 포함하는, 제약 조성물.
- 제17항에 있어서, 상기 생물학적 활성물질은 DNA, RNA, siRNA, 압타머, 단백질, 항체 또는 저분자 화합물인 것을 특징으로 하는, 제약 조성물.
- 제17항에 있어서, 상기 이합체 펩타이드와 생물학적 활성물질은 공유결합으로 연결되어 있거나 또는 비공유결합에 의해 복합체 형태로 존재하는 것인, 제약 조성물.
- 제17항에 있어서, 상기 이합체 펩타이드는 바이오틴 및 스트렙타비딘과 결합된 것인, 제약 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3175363A CA3175363A1 (en) | 2020-04-14 | 2021-04-12 | Novel alpha-helical double-sided cell penetrating peptide and use thereof |
EP21788271.1A EP4137504A4 (en) | 2020-04-14 | 2021-04-12 | NOVEL ALPHA-HELICAL DOUBLE-SIDED CELL PENETRATION PEPTIDE AND ITS USE |
JP2022562522A JP2023523564A (ja) | 2020-04-14 | 2021-04-12 | 新規のアルファ螺旋状両親媒性細胞透過ペプチドおよびこの用途 |
AU2021255623A AU2021255623A1 (en) | 2020-04-14 | 2021-04-12 | Novel alpha-helical double-sided cell penetrating peptide and use thereof |
US17/918,930 US20230242582A1 (en) | 2020-04-14 | 2021-04-12 | Novel alpha-helical double-sided cell penetrating peptide and use thereof |
CN202180042583.2A CN115916801A (zh) | 2020-04-14 | 2021-04-12 | 新型的α螺旋双性细胞穿透肽及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0045454 | 2020-04-14 | ||
KR20200045454 | 2020-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021210868A1 true WO2021210868A1 (ko) | 2021-10-21 |
Family
ID=78084304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004592 WO2021210868A1 (ko) | 2020-04-14 | 2021-04-12 | 신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230242582A1 (ko) |
EP (1) | EP4137504A4 (ko) |
JP (1) | JP2023523564A (ko) |
KR (2) | KR102389603B1 (ko) |
CN (1) | CN115916801A (ko) |
AU (1) | AU2021255623A1 (ko) |
CA (1) | CA3175363A1 (ko) |
WO (1) | WO2021210868A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023063759A1 (ko) * | 2021-10-13 | 2023-04-20 | (주) 캠프테라퓨틱스 | 나노몰 농도에서 세포 내 전달 가능한 미토콘드리아 특이적 펩타이드 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130121958A1 (en) * | 2009-12-21 | 2013-05-16 | Institute Of Microbiology Of The Ascr., V.V.I. | Streptavidin and biotin-based antigen delivery system |
WO2015057009A1 (ko) | 2013-10-17 | 2015-04-23 | 서울대학교산학협력단 | 알파나선형 세포 투과 펩타이드 다합체, 이의 제조방법 및 그 용도 |
KR20170033790A (ko) * | 2015-09-17 | 2017-03-27 | 서울대학교산학협력단 | 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도 |
KR20170085593A (ko) * | 2014-11-28 | 2017-07-24 | 서울대학교산학협력단 | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 |
US20170349628A1 (en) * | 2014-10-02 | 2017-12-07 | Temple University-Of The Commonwealth System Of Higher Education | Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications |
-
2021
- 2021-04-12 JP JP2022562522A patent/JP2023523564A/ja active Pending
- 2021-04-12 US US17/918,930 patent/US20230242582A1/en active Pending
- 2021-04-12 EP EP21788271.1A patent/EP4137504A4/en active Pending
- 2021-04-12 WO PCT/KR2021/004592 patent/WO2021210868A1/ko unknown
- 2021-04-12 CA CA3175363A patent/CA3175363A1/en active Pending
- 2021-04-12 AU AU2021255623A patent/AU2021255623A1/en active Pending
- 2021-04-12 KR KR1020210047128A patent/KR102389603B1/ko active IP Right Grant
- 2021-04-12 CN CN202180042583.2A patent/CN115916801A/zh active Pending
-
2022
- 2022-04-04 KR KR1020220041930A patent/KR20220050848A/ko not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130121958A1 (en) * | 2009-12-21 | 2013-05-16 | Institute Of Microbiology Of The Ascr., V.V.I. | Streptavidin and biotin-based antigen delivery system |
WO2015057009A1 (ko) | 2013-10-17 | 2015-04-23 | 서울대학교산학협력단 | 알파나선형 세포 투과 펩타이드 다합체, 이의 제조방법 및 그 용도 |
KR20160063349A (ko) * | 2013-10-17 | 2016-06-03 | 서울대학교산학협력단 | 알파나선형 세포 투과 펩타이드 다합체,이의 제조방법 및 그 용도 |
US20170349628A1 (en) * | 2014-10-02 | 2017-12-07 | Temple University-Of The Commonwealth System Of Higher Education | Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications |
KR20170085593A (ko) * | 2014-11-28 | 2017-07-24 | 서울대학교산학협력단 | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 |
KR20170033790A (ko) * | 2015-09-17 | 2017-03-27 | 서울대학교산학협력단 | 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도 |
Non-Patent Citations (2)
Title |
---|
KIM ET AL., BIOMACROMOLECULES, 2016 |
See also references of EP4137504A4 |
Also Published As
Publication number | Publication date |
---|---|
CA3175363A1 (en) | 2021-10-21 |
CN115916801A (zh) | 2023-04-04 |
EP4137504A1 (en) | 2023-02-22 |
JP2023523564A (ja) | 2023-06-06 |
KR102389603B1 (ko) | 2022-04-25 |
EP4137504A4 (en) | 2024-06-12 |
AU2021255623A1 (en) | 2022-12-08 |
KR20220050848A (ko) | 2022-04-25 |
KR20210127628A (ko) | 2021-10-22 |
US20230242582A1 (en) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015057009A1 (ko) | 알파나선형 세포 투과 펩타이드 다합체, 이의 제조방법 및 그 용도 | |
EP0382781B1 (en) | Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene | |
WO2014046478A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2016080626A2 (en) | Prodrugs activated by caspase | |
WO2014046490A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
Eggimann et al. | Designed cell penetrating peptide dendrimers efficiently internalize cargo into cells | |
Szabó et al. | Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells | |
AU1063000A (en) | Transport vectors | |
IL186955A (en) | Pharmacologically active peptide conjugates that have a reduced tendency for enzymatic hydrolysis | |
WO2015005723A1 (ko) | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 | |
WO2021210868A1 (ko) | 신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도 | |
WO2022215946A1 (ko) | 세포 투과성 펩타이드 변이체 및 이의 용도 | |
US5863900A (en) | Lhrh antagonists | |
WO2021167308A2 (ko) | 항암제 프로드러그 컨쥬게이트의 새로운 용도 | |
WO2015199511A1 (en) | Novel long-acting insulin analogue and use thereof | |
KR20070108953A (ko) | 펩타이드 벡터 | |
WO2018208125A1 (ko) | 메토트렉세이트와 펩타이드의 결합체 | |
US5084556A (en) | Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene | |
US20180264124A1 (en) | Drug complex | |
WO2022139071A1 (ko) | 신규한 세포 투과성 펩타이드 및 이의 용도 | |
Bánóczi et al. | Synthesis of daunomycin-oligoarginine conjugates and their effect on human leukemia cells (HL-60) | |
KR20240113714A (ko) | 신규한 알파나선형 양면성 세포 투과 펩타이드 및 이의 용도 | |
US20060293242A1 (en) | Transporting of taxoid derivatives through the blood brain barrier | |
CZ20011700A3 (cs) | Benzoxazolové deriváty a léčiva na jejich bázi | |
WO2023277628A1 (ko) | 신규한 세포 투과성 펩타이드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21788271 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3175363 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022562522 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021788271 Country of ref document: EP Effective date: 20221114 |
|
ENP | Entry into the national phase |
Ref document number: 2021255623 Country of ref document: AU Date of ref document: 20210412 Kind code of ref document: A |